MAL-di-EG-Val-Cit-PAB-MMAE Catalog number: BADC-00805

MAL-di-EG-Val-Cit-PAB-MMAE is a potent and targeted compound used in the development of antibody-drug conjugates (ADCs) for cancer therapy. The structure includes a malonic acid (MAL) group, a diethylene glycol (di-EG) spacer, a valine-citrulline (Val-Cit) dipeptide, a para-aminobenzyl (PAB) linker, and the cytotoxic drug MMAE (monomethyl auristatin E). The compound is designed to deliver MMAE selectively to cancer cells through the use of a targeting molecule, typically an antibody. The Val-Cit linker provides enzymatic cleavage by specific proteases present in the tumor microenvironment, ensuring that MMAE is released only in targeted cells, minimizing off-target toxicity and enhancing the therapeutic index of the drug. This approach is widely used to improve the specificity and efficacy of cancer treatments.

A key application of MAL-di-EG-Val-Cit-PAB-MMAE is in overcoming the limitations of traditional chemotherapy. MMAE is a highly potent cytotoxic agent that inhibits microtubule dynamics, leading to cell cycle arrest and apoptosis. However, it is too toxic for systemic use. By attaching MMAE to a targeting antibody via the Val-Cit-PAB linker, the drug is delivered specifically to cancer cells, where it is cleaved and activated. This targeted delivery system reduces systemic exposure to MMAE, minimizing harmful side effects like peripheral neuropathy, and significantly improving the safety and efficacy of chemotherapy. The use of this conjugate is particularly beneficial for treating cancers like lymphoma, breast cancer, and non-small cell lung cancer.

MAL-di-EG-Val-Cit-PAB-MMAE also has significant potential in combination therapies. By combining ADCs such as MAL-di-EG-Val-Cit-PAB-MMAE with immune checkpoint inhibitors or other targeted therapies, a synergistic effect can be achieved. The targeted delivery of MMAE can enhance the anti-tumor activity of immune-modulating agents by reducing the tumor burden, which in turn can make the tumor microenvironment more susceptible to immune attack. This combination approach has shown promise in improving the overall therapeutic outcome, particularly in cancers with high mutational burden or resistance to single-agent therapies. This synergistic use holds great potential for enhancing patient response rates and improving long-term survival.

In addition, MAL-di-EG-Val-Cit-PAB-MMAE is useful in the development of personalized medicine strategies. The conjugate can be designed to target specific tumor markers that are unique to an individual patient's cancer, allowing for the delivery of highly tailored treatments. By incorporating biomarkers such as HER2 or CD19 into the targeting antibody, ADCs like MAL-di-EG-Val-Cit-PAB-MMAE can provide precision medicine solutions, improving the effectiveness of therapy and reducing unnecessary side effects. Personalized approaches using such conjugates enable clinicians to select the most effective treatment plan based on the molecular profile of the patient's tumor, leading to better clinical outcomes.